Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140918

Published: 2020

Journal Articles

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Giovanni Palladini, MD PhD, Stefan Schönland, MD, Giampaolo Merlini, MD, Paolo Milani, MDPhD, Arnaud Jaccard, MD PhD, Frank Bridoux, MD PhD, Wilfried Roeloffzen, MD PhD, M. Teresa Cibeira, MD PhD, Hermine Agis, MD, Monique C. Minnema, MD PhD, Rui Bergantim, MD, Roman Hajek, MD PhD, Cristina João, MD PhD MSc, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Pieter Sonneveld, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140708

Published: 2020

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Georg Jeryczynski, MD, Antonia Eder, Eva-Maria Reitter, MD, Maria-Theresa Krauth, MD, Hermine Agis, MD

Blood (2019) 134 (Supplement_1): 3123.

https://doi.org/10.1182/blood-2019-124681

Published: 2019

Journal Articles

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

Daniel Lechner, MD, Richard Greil, MD, Bernd Hartmann, Maria-Theresa Krauth, MD, Heinz Gisslinger, Ursula Vogl, Leopold Ohler, Hildegard T. Greinix, MD, Siegfried Sormann, Johannes Andel, Ernst Rechberger, Hermine Agis, MD

Blood (2018) 132 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2018-99-116292

Published: 2018

Journal Articles

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Marc S Raab, MD PhD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, MD PhD, Hermann Einsele, MD, Monika Engelhardt, MD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Rollig, MD MSC, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Mark Winderlich, PhD, Christian Peschel, MD

Blood (2018) 132 (Supplement 1): 153.

https://doi.org/10.1182/blood-2018-153

Published: 2018

Journal Articles

Longitudinal Evaluation of Renal Function in Multiple Myeloma

Marlies Antlanger, Thomas Reiter, MD, Eleonore Pablik, Christoph Minichsdorfer, Edit Porpaczy, MD, Susanne Rasoul-Rockenschaub, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2017) 130 (Supplement 1): 5387.

https://doi.org/10.1182/blood.V130.Suppl_1.5387.5387

Published: 2017

Journal Articles

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Thomas Reiter, MD, Marlies Antlanger, Alexandra Böhm, Wolfgang Lamm, Max Gornicec, Ella Willenbacher, MD, David Nachbauer, Werner Rabitsch, Daniel Lechner, MD, Hildegard Greinix, Felix Keil, MD, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2017) 130 (Supplement 1): 5424.

https://doi.org/10.1182/blood.V130.Suppl_1.5424.5424

Published: 2017

Journal Articles

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, MD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, Hermann Einsele, MD, Monika Engelhardt, MD PhD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Jan Endell, PhD, Rainer Boxhammer, PhD, Christian Peschel, MD

Blood (2016) 128 (22): 1152.

https://doi.org/10.1182/blood.V128.22.1152.1152

Published: 2016

Journal Articles

Does Renal Failure Affect Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma?

Marlies Antlanger, Thomas Reiter, Wolfgang Lamm, Werner Rabitsch, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2016) 128 (22): 4642.

https://doi.org/10.1182/blood.V128.22.4642.4642

Published: 2016

Journal Articles

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

Marc S Raab, MD PhD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor W Blau, MD PhD, Hermann Einsele, MD, Monika Engelhardt, MD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja C. Weisel, Pia Klöpfer, MD, Dominika Weinelt, MD, Stefan Härtle, PhD, Christian Peschel, MD

Blood (2015) 126 (23): 3035.

https://doi.org/10.1182/blood.V126.23.3035.3035

Published: 2015

Journal Articles

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Karl J. Aichberger, MD, MSci, Susanne Herndlhofer, Hermine Agis, MD, Wolfgang R. Sperr, MD, Werner Rabitsch, MD, Harald Esterbauer, MD, PhD, Paul Knoebl, MD, Christian Sillaber, MD, Ulrich Jaeger, MD, Peter Valent, MD

Blood (2007) 110 (11): 4556.

https://doi.org/10.1182/blood.V110.11.4556.4556

Published: 2007

Journal Articles

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Hermine Agis, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 3516.

https://doi.org/10.1182/blood.V106.11.3516.3516

Published: 2005

Journal Articles

Histamine Monitoring in Patients with CML during Treatment with Imatinib: Comparison to Monitoring by Cytogenetics and BCR/ABL.

Hermine Agis, MD, Susanne Herndlhofer, Hans Semper, Hendrati Pirc-Donoewenater, PhD, Oskar Haas, MD, Christine Mannhalter, MD, Harald Esterbauer, MD, PhD, Wolfgang R. Sperr, MD, Klaus Geissler, MD, Peter Valent, MD

Blood (2005) 106 (11): 4836.

https://doi.org/10.1182/blood.V106.11.4836.4836

Published: 2005

Journal Articles

Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.

Hermine Agis, md, Maria T. Krauth, md, Leonhard Muellauer, md, Lawrence B. Schwartz, md, Hans P. Horny, md, Peter Valent, md

Blood (2004) 104 (11): 4754.

https://doi.org/10.1182/blood.V104.11.4754.4754

Published: 2004

Journal Articles

Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.

Maria T. Krauth, md, Hermine Agis, md, Karl J. Aichberger, md, Ingrid Simonitsch, md, Leonhard Muellauer, md, Matthias Mayerhofer, md, Hans P. Horny, md, Peter Valent, md

Blood (2004) 104 (11): 4755.

https://doi.org/10.1182/blood.V104.11.4755.4755

Published: 2004

NARROW

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Longitudinal Evaluation of Renal Function in Multiple Myeloma

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Does Renal Failure Affect Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma?

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Histamine Monitoring in Patients with CML during Treatment with Imatinib: Comparison to Monitoring by Cytogenetics and BCR/ABL.

Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.

Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only